| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
The specific molecular target of Kauran-16,17-diol has not been identified in publicly available sources. As an ent-kaurane diterpenoid, it may interact with various cellular targets involved in inflammation, cancer, or microbial growth. The compound's mechanism of action and target specificity would need to be determined through experimental studies. Researchers interested in this compound should consult the original publications for detailed target information.
|
|---|---|
| ln Vitro |
In MCF-7 cells, Kauran-16,17-diol (ent-Kauran-16β,17-diol) causes an up-regulation of E2F1 and down-regulates Bcl-2 by disrupting the Ap-2α/Rb transcription activating complex[1].
In vitro data for Kauran-16,17-diol is not publicly available. As a diterpenoid, it may exhibit anti-inflammatory, anticancer, or antimicrobial activities in cell-based assays. However, specific in vitro activity data, including IC50 values or efficacy measurements, have not been reported in the available literature. Researchers interested in the biological activity of this compound should consult the original research articles. |
| ln Vivo |
In vivo data for Kauran-16,17-diol is not publicly available. As a natural product derivative, it may have been tested in animal models for various pharmacological activities, but these results have not been published or are not accessible in the current literature. Researchers interested in the in vivo properties of Kauran-16,17-diol should consult the original research articles or contact the supplier for additional information.
|
| Enzyme Assay |
The in vitro experimental protocols for Kauran-16,17-diol would depend on the specific biological assay being performed. Typical assays for diterpenoid research compounds include anti-inflammatory assays (measuring cytokine production), anticancer assays (cell viability), or antimicrobial assays (minimum inhibitory concentration). The compound would be dissolved in an appropriate solvent such as DMSO and tested at varying concentrations. However, specific protocols for Kauran-16,17-diol have not been published.
|
| Cell Assay |
Cellular assays for Kauran-16,17-diol would depend on the intended biological application. Researchers would typically treat cells with varying concentrations of the compound and measure relevant endpoints such as cell viability, inflammatory cytokine production, or microbial growth inhibition. However, specific cellular assay protocols for Kauran-16,17-diol are not available in the public domain. Researchers should develop their own protocols based on their experimental needs.
|
| Animal Protocol |
In vivo protocols for Kauran-16,17-diol would depend on the specific animal model and research question. Typical studies might involve administration of the compound via oral, intraperitoneal, or intravenous routes, followed by assessment of efficacy in disease models. However, specific in vivo protocols for Kauran-16,17-diol have not been published in the available literature. Researchers should consult the original studies or contact the supplier for guidance.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Kauran-16,17-diol is not publicly available. As a diterpenoid, its absorption, distribution, metabolism, and excretion properties would typically be characterized in preclinical studies. However, specific PK parameters such as half-life, bioavailability, and clearance have not been reported in the available literature. Researchers interested in the pharmacokinetic properties of this compound should consult the original research articles.
|
| Toxicity/Toxicokinetics |
Toxicity data for Kauran-16,17-diol is not publicly available. As a research compound, its safety profile would typically be evaluated in in vitro cytotoxicity assays and in vivo tolerability studies. However, specific toxicity data has not been reported in the available literature. As with all research compounds, Kauran-16,17-diol is intended for research use only and not for human therapeutic applications.
|
| References |
|
| Additional Infomation |
Coalane-16α,17-diol has been reported in Aristolochia debilis, Fritillaria thunbergii, and other organisms with available data.
Kauran-16,17-diol (ent-Kauran-16β,17-diol; CAS 16836-31-0) is a diterpenoid compound with limited publicly available information. It is an ent-kaurane diterpenoid, a class of natural products known for various pharmacological activities. The compound's molecular target, biological activity, and pharmacokinetic properties have not been detailed in the current literature. Researchers interested in Kauran-16,17-diol should consult specialized chemical databases or the original literature. The compound is intended for research use only. |
| Molecular Formula |
C20H34O2
|
|---|---|
| Molecular Weight |
306.48
|
| Exact Mass |
306.256
|
| CAS # |
16836-31-0
|
| PubChem CID |
13816761
|
| Appearance |
White to off-white solid powder
|
| Density |
1.09g/cm3
|
| Boiling Point |
422.3ºC at 760mmHg
|
| Flash Point |
186.8ºC
|
| Vapour Pressure |
6.7E-09mmHg at 25°C
|
| Index of Refraction |
1.55
|
| LogP |
4.142
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
22
|
| Complexity |
472
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
C[C@@]12CCCC([C@H]1CC[C@]34[C@H]2CC[C@H](C3)[C@](C4)(CO)O)(C)C
|
| InChi Key |
LCYWCTWYVKIBSA-URTLRTLISA-N
|
| InChi Code |
InChI=1S/C20H34O2/c1-17(2)8-4-9-18(3)15(17)7-10-19-11-14(5-6-16(18)19)20(22,12-19)13-21/h14-16,21-22H,4-13H2,1-3H3/t14-,15-,16+,18-,19+,20+/m1/s1
|
| Chemical Name |
(1S,4R,9R,10R,13R,14R)-14-(hydroxymethyl)-5,5,9-trimethyltetracyclo[11.2.1.01,10.04,9]hexadecan-14-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2629 mL | 16.3143 mL | 32.6286 mL | |
| 5 mM | 0.6526 mL | 3.2629 mL | 6.5257 mL | |
| 10 mM | 0.3263 mL | 1.6314 mL | 3.2629 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
